Cardiff Oncology appoints Dr. Roger Sidhu as CMO; to share CRDF-004 data on July 29

Cardiff Oncology, Inc.

Dr. Fairooz Kabbinavar stepped down as CMO effective June 13, 2025; will remain as advisor.
Dr. Roger Sidhu appointed CMO; previously at Amgen, Treadwell Therapeutics, Roivant Sciences.
Sidhu receives $515K base salary, 45% target bonus, and option for 600K shares at $3.86 vesting over 4 years.
Company to report additional clinical data from Phase 2 CRDF-004 trial in RAS-mutated mCRC on July 29, 2025.

item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Fairooz Kabbinavar

Chief Medical Officer

CRDF · Cardiff Oncology, Inc.

Effective: 2025-06-13
Successor: Dr. Roger Sidhu
Filed: Jun 17, 2025 23:59 UTC

On June 13, 2025, Dr. Fairooz Kabbinavar and Cardiff Oncology, Inc. (the “Company”) agreed that he would be stepping down from his position as Chief Medical Officer.

Appointed

Dr. Roger Sidhu

Chief Medical Officer

CRDF · Cardiff Oncology, Inc.

Effective: 2025-06-17
Filed: Jun 17, 2025 23:59 UTC

On June 17, 2025, the Company announced that it has appointed Dr. Roger Sidhu as its new Chief Medical Officer and entered into an employment agreement with Dr. Sidhu on June 16, 2025 (the “Sidhu Employment Agreement”).

Source: SEC EDGAR

accession 0000950170-25-087369

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.